Defects in STK9, a dual-specificity serine/threonine kinase, are a cause of atypical Rett syndrome.
Rett syndrome is an X-linked dominant disease.
It is a progressive neurologic developmental disorder and one of the most common causes of mental retardation in females.
Patients appear to develop normally until 6 to 18 months of age, then gradually lose speech and purposeful hand movements and develop microcephaly, seizures, autism, ataxia, intermittent hyperventilation, and stereotypic hand movements.
After initial regression, the condition stabilizes and patients usually survive into adulthood.
Rett syndrome due to CDKL5-associated mutations is characterized by a severe early-onset phenotype and atypical features such as infantile spasms.
Applications:Suitable for use in Western Blot, Immunohistochemistry and FLISA.
Other applications have not been tested.
Recommended Dilution:Immunohistochemistry: Formalin-fixed, paraffin-embedded sections Optimal dilutions to be determined by the researcher.
Storage and Stability:Store product at 4°C if to be used immediately within two weeks.
For long-term storage, aliquot to avoid repeated freezing and thawing and store at -20°C.
Aliquots are stable at -20°C for 12 months after receipt.
Dilute required amount only prior to immediate use.
Further dilutions can be made in assay buffer.
Caution: FITC conjugates are sensitive to light.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Note: Applications are based on unconjugated antibody.
仕様
Size：200ul
Host：rabbit
Source Antibody：human
Grade：Affinity Purified
Purity：Purified by Protein A/G affinity chromatography.
Form：Supplied as a liquid in PBS, pH 7.2. No preservative added. Labeled with Fluorescein isothiocyanate (FITC).
Specificity：Recognizes human CDKL5.
Isotype：IgG
Calc Applications Abbrev：FLISA IHC WB
Calc Crossreactivity：Hu
Immunogen：KLH-conjugated synthetic peptide mapping to a fragment of residues within amino acids 982-1012 in the C-terminal region of human CDKL5.
